Schonfeld Strategic Advisors’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Schonfeld Strategic Advisors’s Portfolio DMAAR Stock Details DMAAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-117,480	Closed	-$22K	–	2788
2025 Q4	$22K	Sell	117,480 -29,527	-20%	-$5.73K	﹤0.01%	1924
2025 Q3	$32K	Sell	147,007 -267,485	-65%	-$49.7K	﹤0.01%	2089
2025 Q2	$49.8K	Buy	414,492 +214,492	+107%	+$27.6K	﹤0.01%	1884
2025 Q1	$26K	Buy	+200,000	New	+$28.1K	﹤0.01%	2095

Other funds holding DMAAR

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Schonfeld Strategic Advisors's DMAAR Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Drugs Made In America Acquisition Corp Rights (DMAAR) in Q1 2026, closing a stake of 117,480 shares — an estimated $22K sold.

Schonfeld Strategic Advisors first reported a position in DMAAR in Q1 2025 and held it in 4 quarters. The position peaked at $49.8K in Q2 2025. 35 funds tracked by Wall St. Rank hold DMAAR as of Q1 2026.

Schonfeld Strategic Advisors reported no remaining Drugs Made In America Acquisition Corp Rights position as of Q1 2026 after selling out during the quarter.
Schonfeld Strategic Advisors sold 117,480 Drugs Made In America Acquisition Corp Rights shares in Q1 2026, an estimated $22K.
Schonfeld Strategic Advisors first reported a position in Drugs Made In America Acquisition Corp Rights in Q1 2025 and held it in 4 quarters.
Schonfeld Strategic Advisors's Drugs Made In America Acquisition Corp Rights position peaked at $49.8K in Q2 2025.
35 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.